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Background—Identification of people with hypertrophic cardiomyopathy (HCM) who are at risk 
of sudden cardiac death (SCD) and require prophylactic implantable cardioverter defibrillator 
(ICD) is challenging. In 2014, the European Society of Cardiology (ESC) proposed a new risk 
stratification method based on a risk prediction model (HCM Risk-SCD) which estimates the 5-
year risk of SCD. The aim was to externally validate the 2014 ESC recommendations in a 
geographically diverse cohort of patients recruited from North America, Europe, The Middle 
East and Asia.
Methods—This was an observational, retrospective, longitudinal cohort study.
Results—The cohort consisted of 3703 patients. Seventy three (2%) patients reached the SCD 
end-point within 5 years of follow-up [5-year incidence 2.4% (95% CI 1.9, 3.0)]. The validation 
study revealed a calibration slope of 1.02 (95% CI 0.93 to 1.12); C-index 0.70 (95% CI 0.68 to 
0.72) and D-statistic 1.17 (95% CI 1.05 to 1.29). In a complete case analysis (n= 2147; 44 SCD 
end-points at 5 years) patients with a predicted 5-year risk of <4% (n=1524; 71%) had an 
observed 5-year SCD incidence of 1.4% (95% CI 0.8, 2.2); paWLHQWVZLWKDSUHGLFWHGULVNRI
(n=297; 14%) had an observed SCD incidence of 8.9% (95% CI 5.96, 13.1) at 5 years. For every 
,&'LPSODQWDWLRQVLQSDWLHQWVZLWKDQHVWLPDWHG\HDU6&'ULVNSDWLHQWFDQ
potentially be saved from SCD. 
Conclusions—This study confirms that the HCM Risk–SCD model provides accurate prognostic 
information which can be used to target ICD therapy in patients at the highest risk of SCD.
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x This is a large, international, multi-centre study designed to validate the 2014 European 
Society of Cardiology guidelines on sudden cardiac death (SCD) prevention in 
hypertrophic cardiomyopathy (HCM) 
x The guidelines discriminate high from low risk patients reasonably well
x There is a good agreement between predicted risk and subsequent events 
What are the clinical implications?
x Patients with a 5-\HDU6&'ULVNVKRXOGbe offered an ICD
x Patients with a 5-\HDU6&'ULVNVKRXOGEHUHJXODUO\UH-assessed
x In intermediate risk patients (5-year risk of >4% to <6%) an ICD may be considered 
following an appraisal of the lifelong risks and benefits of device therapy 





Hypertrophic cardiomyopathy (HCM) causes sudden cardiac death (SCD) in young and 
otherwise well individuals.1,2 Prophylactic treatment with implantable cardioverter defibrillators 
(ICD) is the current standard of care for people with HCM deemed to be at high risk of SCD, but 
the identification of individuals most likely to benefit from device implantation is challenging.1,2
In 2014, the European Society of Cardiology (ESC) proposed a new approach to risk prediction 
that uses a clinical risk tool (HCM Risk-SCD) to estimate a five-year risk of sudden cardiac 
death. Although internally validated in a large multicentre cohort,3 papers published since the 
ESC recommendations have been inconsistent with respect to the performance of the ESC 
guidelines in different populations.4-7 The aim of this study was to validate the 2014 ESC 
recommendations in a large, geographically diverse cohort recruited from centres in North 
America, Europe, The Middle East and Asia.
Methods
Study design
This international external validation study of the 2014 European Society of Cardiology 
guideline on sudden cardiac death prevention in hypertrophic cardiomyopathy (EVIDENCE-
HCM) used a retrospective, multi-center, longitudinal cohort of patients. The HCM Risk-SCD 
model was statistically validated and the clinical impact of the 2014 ESC SCD risk stratification 
guidelines examined using SCD end-points within 5 years of baseline clinical evaluation.  
The study conforms to the principles of the Helsinki declaration. The sponsors of this study did 
not have a role in study design, data collection, analysis or interpretation. COM, RO, FJ, and PE 
had access to all data and final responsibility for submission of the manuscript. The authors from 
each participating center guarantee the integrity of data from their institution and had approval 





from a local ethics committee/internal review board. Subjects gave informed consent in 
accordance to local protocol. All investigators have agreed to the manuscript as written. The 
data, analytic methods, and study materials will not be made available to other researchers for 
purposes of reproducing the results or replicating the procedure. 
Study population
The study cohort consisted of consecutively evaluated patients with HCM at 14 participating 
centers in the USA, Europe, the Middle East and Asia (supplementary table 1). Included patients 
were evaluated between 1970 and 2014 (most patients (69%) were evaluated from 2000 
onwards; supplementary figure 1). None of the patients were included in the original HCM Risk-
SCD development study.3 2QO\DGXOWSDWLHQWV\HDUVRIDJHZLWKRXWSULRUYHQWULFXODU
fibrillation or sustained ventricular tachycardia were studied.  
+&0ZDVGHILQHGDVDPD[LPXPOHIWYHQWULFXODUZDOOWKLFNQHVV0:7PPXQH[SODLQHGE\
abnormal loading conditions8 or in accordance with published criteria for the diagnosis of 
disease in relatives of patients with unequivocal disease.9 Patients known to have metabolic 
diseases or syndromic causes of HCM were excluded. 
Patient assessment and data collection 
Patients underwent clinical assessment, pedigree analysis, physical examination, 
electrocardiography (resting and ambulatory) and transthoracic echocardiography. Data were 
collected independently at each participating center using the same methodology. 
Predictor variables and calculation of 5 year risk of SCD 
The following predictor variables were recorded at the time of first evaluation at each 
participating center:
1. Age at time of evaluation (years)





2. Family history of SCD (FHSCD) in 1 or more first degree relatives under 40 years of age or 
SCD in a first degree relative with confirmed HCM (post or ante-mortem diagnosis) at any age.
3. MWT in the parasternal short and long-axis plane using 2-D echocardiography (mm)
4. Left atrial diameter (LAd) by M-Mode or 2D echocardiography in the parasternal long axis 
plane (mm).
5. Maximal instantaneous left ventricular outflow tract gradient (LVOTgmax) at rest and with 
Valsalva provocation (irrespective of concurrent medical treatment) using continuous wave 
Doppler echocardiography (mmHg) 
6. Non-VXVWDLQHGYHQWULFXODUWDFK\FDUGLD1697GHILQHGDVFRQVHFXWLYHYHQWULFXODUEHDWVDWD
UDWHRIEHDWVSHUPLQXWHDQGVLQGXUDWLRQRQ+ROWHUPRQLWRULQJPLQLPXPGXUDWLRQ
hours) at or prior to first evaluation. 
7. Unexplained syncope at or prior to first evaluation. 





where PI is the prognostic index = 0.15939858*MWT - 0.00294271*MWT2 + 0.0259082* LAd 
+ 0.00446131*LVOTgmax + 0.4583082*FHSCD + 0.82639195*NSVT +
0.71650361*Unexplained syncope - 0.01799934*Age.  
In keeping with clinical practice and the 2014 ESC recommendations 
(http://www.doc2do.com/hcm/webHCM.html), patients with extreme clinical characteristics who 
were under-represented in the published development cohort were not used for validation but are 
reported separately. The extreme clinical characteristics were defined a priori as left atrial 
diameter >67mm, left ventricular outflow tract gradient >154mmHg, maximal left ventricular 








The study end-point was SCD or an equivalent event. SCD was defined as witnessed sudden 
death with or without documented ventricular fibrillation or death within one hour of new 
symptoms or nocturnal deaths with no antecedent history of worsening symptoms.10 Aborted 
SCD during follow-up and appropriate ICD shock therapy were considered equivalent to SCD. 
11-16 As in previous studies, ICD shocks were considered appropriate if the treated 
tachyarrhythmia was ventricular in origin.11-16 The cause of death was ascertained by the treating 
cardiologists at each center using hospital and primary health care records, death certificates, 
post-mortem reports and interviews with witnesses. Deaths were assessed without knowledge of 
HCM Risk-SCD estimates. 
General statistical methods
All statistical analyses were carried out using STATA (version 14). Variables are expressed as
mean ± standard deviation (SD), median (25th, 75th percentiles) or counts and percentages as 
appropriate. The follow-up time for each patient was calculated from the date of their first 
evaluation to the date of reaching the study endpoint, or death from another cause, or to the date 
of their most recent evaluation. The annual event rate was calculated by dividing the number of 
patients reaching the endpoint by the total follow-up period for that endpoint. The cumulative 
probability for the occurrence of an outcome was estimated using the Kaplan Meier method. 
Missing data 
To determine the degree of bias due to missing data, the characteristics of patients with missing 
information were compared with those with complete information. Logistic regression was used 





to identify the predictors of missingness. Data were assumed to be missing at random and values 
for the missing predictors were imputed using multiple imputation techniques based on chained 
equations.17 All predictors of missingness were included in the multiple imputation model, 
together with the outcome, all pre-specified predictors of the risk model, and the estimate of the 
cumulative hazard function.18 A total of 45 imputed data sets were generated and the estimates 
were combined using Rubin’s rules.19
HCM Risk-SCD model validation 
The calibration slope was used to assess the degree of agreement between the observed and 
predicted hazards of SCD.20 A value close to 1 suggests good overall agreement. Graphical 
comparisons of the observed and predicted SCD at 5 years by risk groups (group cut-offs: 0-2%, 
2-4%, 4-6% and >6% 5-year risk of SCD) were performed. The C-index as proposed by Uno and 
D-statistic were used to measure how well the model discriminated between patients with high 
and low risk of SCD.21,22 A value of 0.5 for C-index indicates no discrimination and a value 
equal to 1 indicates perfect discrimination. The D-statistic quantifies the observed separation 
between subjects with low and high predicted risks as predicted by the model and can be 
interpreted as the log hazard ratio for having SCD between the low and high risk groups of 
patients. A model with no discriminatory ability has a value of 0 for D-statistic, with increasing 
values indicating greater separation.  
Sensitivity analysis: septal reduction therapy 
Patients with drug refractory symptoms secondary to outflow tract obstruction frequently 
undergo septal reduction therapy after baseline assessment which can potentially decrease SCD 
risk predictions by relieving LVOTgmax and reducing MWT. 3 To assess the impact of septal 





reduction therapy on the predictive performance of the model, HCM Risk-SCD was validated 
without patients undergoing septal reduction therapy within 5 years of follow-up. 
Complete case analysis: HCM Risk-SCD and SCD end-points at 5 years  
The incidence of the SCD end-point is reported in patients with all the data required to calculate 
the 5-year SCD risk. SCD end-SRLQWVDUHH[DPLQHGLQWKUHHFDWHJRULHVWR




Clinical characteristics of the cohort
The study enrolled a total of 3902 patients including 199 (5%) with extreme clinical 
characteristics. The validation cohort consisted of 3703 patients; the baseline clinical 
characteristics are shown in table 1. The cohort was composed of 87 (2.4%) patients <20 years of 
age, 278 (7.5%) patients aged 20 to <30 years, 529 (14.3%) aged 30 to <40 years, 703 (19%) 
aged 40 to <50 years, 861(23.3%) aged 50 to <60 years, 806 (21.8%) aged 60 to <70 years and 
439 (11.9%) aged 70 to 80 years. One hundred and fifty-one patients (4%) were diagnosed on the 
basis of familial criteria.9 Data on self-reported ethnicity were available in 3177 (86%) patients; 
the cohort was composed of 2631 white (71%), 385 Asian (10%), 99 black (3%) and 62 patients 
of mixed/other ethnicity (2%) with 14% missing data. During follow-up, 397 (11%) patients 
received an ICD.





SCD end-points during follow-up
During a follow-up period of 28,186 patient years (median 5.9 (3.0, 10) years; range 2 days 
[SCD end-point] to 39.6 years [censored]), 159 patients (4%) reached the SCD end-point with an 
annual rate of 0.6% (95% CI: 0.5, 0.7). Appropriate ICD shocks contributed 42 SCD end-points 
(26%). Seventy three (2%) patients reached the SCD end-point within 5 years of follow-up, with 
a 5-year incidence of 2.4% (95% CI: 1.9, 3.0). Twenty SCD end-points within 5 years occurred 
in patients with FHSCD but there was no familial clustering of end-points (defined as >2 SCD in 
individuals from the same family group). The clinical characteristics of patients with and without 
the SCD end-point are shown in table 2. 
Missing data 
Missing data were observed in six of the seven HCM Risk-SCD predictor variables: NSVT 30%, 
LVOTgmax 17%, unexplained syncope 2%, FHSCD 2%, LAd 10% and MWT 0.8%. Complete 
data for the calculation of HCM Risk-SCD estimates were available in 2147 (58%) patients. 
Missingness was associated with systolic blood pressure, alcohol septal ablation, myectomy, 
ethnicity, NYHA III/IV, ICD, pacemaker, amiodarone atrial fibrillation, left ventricular end-
diastolic pressure, centre and all cause mortality.
Model validation 
Validation revealed a calibration slope of 1.02 (95% CI 0.93 to 1.12). Figure 1 illustrates a good 
agreement between the observed and predicted risk of sudden cardiac death at 5 years, 
particularly in the low risk groups. The C-index was 0.70 (95% CI 0.68 to 0.72). The D-statistic 
was 1.17 (95% CI 1.05 to 1.29) suggesting that the hazard of SCD is 3.2 times higher in the high 
risk group compared to the hazard in the low risk group as predicted by the model. 





Sensitivity analysis: septal reduction therapy 
A total of 670 (18%) patients had septal reduction therapy during their clinical course (542 
myectomies and 150 alcohol septal ablations, with 22 patients having both procedures). Their 
baseline clinical characteristics are shown in table 3. Of the 518 patients who had septal 
reduction therapy within 5 years of first evaluation, 85% were low or intermediate risk and 8 
(1.5%) reached the SCD end-point within that period. The calibration slope for the model after 
excluding patients with septal reduction therapy within 5 years of baseline evaluation was 1.09 
(95% CI: 0.99, 1.18), the C-index was 0.71 (95%: CI 0.68, 0.73) and D-statistic was 1.17 (95% 
CI: 1.0, 1.25). 
Complete case analysis: HCM Risk-SCD and SCD end-points at 5 years 
The 2147 (58%) patients with complete data had a median 5-year risk of SCD of 2.6% (1.7, 4.4). 
During a follow-up period of 14,496 years (median 5.4 (2.8, 8.5) years), a total of 96 SCD end-
points were observed and 44 patients reached the SCD end-point within 5 years (table 4, figures 
2 and 3). Patients not reaching the SCD end-point at 5 years (n=2103) had a median predicted 5-
year SCD risk of 2.6% (1.7%, 4.3%), whilst the corresponding calculated risk for those reaching 
the SCD end-point (n=44) was 6.2% (3.2%, 8.6%). The majority (28/44; 64%) of SCD end-
points within 5 years of baseline evaluation occurred in patients with a 5-year risk oIKLJK
and intermediate risk groups) and although only 14% of patients had a HCM-5LVN6&'
(high risk group), these patients contributed 52% of SCD end-points. Intermediate risk patients 
formed 15% of the cohort (n=326) and included 195 patients with a calculated risk of 4.0% to 
4.99% with 1 (0.5%) SCD end-point within 5 years of baseline evaluation. In the remaining 131 
intermediate risk patients who had a predicted risk of 5.0% to 5.99%, 4 (3%) had a SCD end-
point within 5 years.  





Of the 623 patieQWVZLWK6&'ULVNDW\HDUVH[SHULHQFHGD6&'HQG-point which 
suggests that for every 22 (623/28) ICD implantations in this group, 1 patient can potentially be 
VDYHGIURP6&'LQWKDWWLPHSHULRG2IWKHSDWLHQWVZLWK6&'ULVNDW\HDUV7
experienced a SCD end-point which suggests that for every 16 (428/27) ICD implantations, 1 
SDWLHQWFDQSRWHQWLDOO\EHVDYHGIURP6&'DW\HDUV2IWKHSDWLHQWVZLWK6&'ULVNDW
5 years, 23 experienced a SCD end-point suggesting that for every 13 (297/23) ICD 
implantations in this group of patients, 1 patient can potentially be saved from SCD at 5 years. 
Of the 1524 patients with <4% SCD risk at 5 years, 16 experienced a SCD end-point suggesting 
that for every 95 (1524/16) patients not implanted an ICD, 1 can potentially die suddenly within 
5 years.
SCD end-points in patients with extreme clinical characteristics
A group of 199 patients (199/3902; 5%) had extreme clinical characteristics, including 111 
patients aged >80years, 31 patients with LVOTgmax >154mmHg, 28 patients with LAd >67mm 
and 34 patients with MWT>35mm (5 patients had more than one outlying clinical characteristic). 
The baseline clinical characteristics of these patients are shown in table 1.
During a follow-up period of 1,102 patient years (median 4.5 (2.1, 7.5) years; range 6 days [SCD 
end-point] to 24.0 years [censored]), 16 patients (8%) reached the SCD end-point. Nine (4%) 
patients reached the SCD end-point within 5 years of baseline assessment. The annual rate of 
SCD end-point was 1.5% (95% CI: 0.9, 2.4) with a 5-year cumulative incidence of 5.9% (95% 
CI: 3.0, 11.1). Appropriate ICD shocks did not contribute to SCD end-points. Seven (7/16; 44%) 
SCD end-points occurred in patients aged >80 years. 






This study demonstrates that HCM Risk-SCD provides accurate SCD risk estimates in patients 
recruited in multiple different localities around the World and illustrates the positive impact of 
the 2014 ESC recommendations on clinical decision making. Specifically, it shows that the risk-
benefit ratio for ICD implantation is most favourable in individuals with an estimated 5-year risk 
RI
 The clinical usefulness of the 2014 ESC guidelines for sudden death prevention is 
dependent on the performance of the HCM Risk-SCD tool and external validation studies are 
essential to demonstrate the accuracy of its predictions in diverse patient populations. HCM 
Risk-SCD performance was similar to that reported in the original study and is consistent with 
other several smaller external validation cohorts from Europe and South America.4-6 An 
exception is a study of patients from two North American centres in which HCM Risk-SCD had 
a high negative predictive value but was less reliable in predicting long term outcomes.7
However, direct comparison with the present analysis is difficult as the North American study 
did not report discrimination, calibration or end-points within 5 years of baseline evaluation.7
This study shows that HCM Risk-SCD can be used to avoid unnecessary ICD implants in 
low risk patients. The large majority of HCM patients had a 5-year risk of SCD of <4% and the 
very low SCD end-point rate in this patient subgroup, reported in this and other studies,4,5,7
supports the 2014 ESC recommendation not to implant an ICD in individuals with a low 
estimated risk.2 Conversely, patients with a predicted 5-\HDUULVNRI6&'IRUPHGDVPDOO
subgroup which had the highest event rate and the largest absolute number of events.2 In patients 
with a high estimated 5 year risk, the predicted event rates were slightly overestimated, but this is 





less of a problem in clinical practice as this group of patients still KDGWKHKLJKHVWHYHQWUDWH
at 5 years) and as a result have the greatest benefit from prophylactic ICD therapy.  
 Since there is no consensus on the absolute SCD risk that justifies ICD therapy, there are 
some patients in whom clinical decision making is more complex and determined by more than a 
simple estimation of SCD risk. This is reflected in the 2014 ESC guidelines in the form of an 
intermediate risk category (5-\HDUULVNRIWRLQZKLFKDQ,&'PD\EHFRQVLGHUHG
following a detailed clinical assessment and an appraisal of the lifelong risks and benefits of 
device therapy. This study suggests that most intermediate risk patients can be managed 
conservatively, but ICDs have the potential to prevent some sudden deaths in this subgroup, 
especially in those with a 5-\HDUULVNRI7KHGRZQVLGHRIXVLQJDORZHUULVNWKUHVKROGIRU
ICD implantation is the greater healthcare cost and unnecessary exposure of more individual 
patients to the long-term complications of devices.
As patients with HCM are generally young, it is reasonable to conjecture that some will 
change their risk profile during follow-up, thereby violating one of the model’s basic 
assumptions. To account for this, the 2014 ESC guidelines recommend that patients seek medical 
attention if their clinical condition changes and that patients should be routinely re-assessed 
every 12-24 months.2 While it will be challenging, future iterations of the HCM Risk-SCD 
model may be able to test its performance beyond 5 years if a sufficient number events are 
observed.  
Patients with extreme values for individual risk factors were underrepresented in the 
original HCM Risk-SCD development cohort3 and consequently the 2014 ESC guidelines do not 
recommend use of the model in such patients.2 Patients with extreme clinical characteristics were 
also uncommon in this study which implies that the 2014 ESC guidelines are applicable to most 





patients seen in clinical practice. Furthermore, most were >80 years of age, a group in whom 
ICD implantation is frequently inappropriate due to co-morbid conditions.  
 Patients undergoing septal reduction therapy were more frequent in this study (18%) than 
in the development cohort (9%).3 Even though septal reduction therapy may have an impact on 
disease outcomes, the sensitivity analysis in this study suggests that the accuracy of HCM Risk-
SCD predictions is not significantly affected by septal reduction therapy in the short term. These 
data suggest that SCD risk stratification should be undertaken independently but in parallel with 
the management of symptomatic left ventricular outflow tract obstruction. The small number of 
SCD end-points in this subgroup does not allow an examination of the prognostic impact of 
septal reduction or a direct comparison of SCD rates following myectomy and alcohol septal 
ablation.  
As with other widely used clinical risk tools, it is essential that HCM Risk-SCD and the 
2014 ESC guidelines continue to be the subject of constant reassessment in diverse patient 
populations to ensure accuracy in varied clinical scenarios. Risk stratification can potentially be 
improved by examining the incremental predictive value of other patient characteristics such as 
genotype and myocardial scar burden in future studies.23,24 Despite the promise of future 
improvements there will always be inherent uncertainty exemplified by sudden deaths in 
apparently low risk patients and lack of events in high risk patients with past and present risk 
stratification strategies.25,26 No risk stratification strategy will ever be able to predict all sudden 
deaths but quantification of risk enhances the shared decision making process and may aid the 
development of an effective decision making tool in the future.27
This study has a number of limitations. A retrospective, multi-center design was essential 
since the low SCD rate makes prospective validation studies challenging as large number of 





patients need to be followed up for prolonged time periods. Despite the size of the study cohort, 
there were only 74 SCD end-points within 5 years. However, the narrow 95% CIs of the 
validation measures suggest that these have been estimated with reasonable precision. This 
validation study had more missing data that the original development study, but appropriate 
statistical techniques were used to correct for this. Patients aged 16-20 years were relatively 
underrepresented and the validity of the model in this population may require further study.  
Conclusions
This external validation study shows that the HCM Risk-SCD model and 2014 ESC guidelines 
provide accurate prognostic information in patients with HCM which can be used to identify 
patients with a high risk of potentially fatal ventricular arrhythmia in the short to medium term. 
While no risk stratification strategy can predict all events, quantification of risk enhances the 
shared decision making process and provides the basis for consistent and effective treatment 
choices.
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Table 1. Baseline clinical characteristics

















Number of patients 3703 199 3675
Male 2241 (61%) 89 (45%) 2349 (64%)
Age; years 52 ±15 70 ±19 48 ±17
NYHA III/IV 660 (19%) 63 (32%) 426 (12%)
Prior Myectomy 77 (2%) 5 (3%) 34 (1%)
Prior Alcohol septal ablation 23 (0.6%) 0 10 (0.3%)
Amiodarone 297 (8%) 17 (9%) 468 (13%)
ICD 123 (3%) 7 (4%) 42 (1%)
Permanent /persistent AF 433 (12%) 34 (17%) 366 (10%)
NSVT 582 (22%) 39 (31%) 634 (17%)
LA diameter; mm 43±8 49±12 44±8
LVOTgmax; mmHg 11 (7, 55) 36 (9,100) 12 (5, 49)
LVedd; mm 45±7 44±7 45±7
MWT; mm 20±4 23±8 20±5
FS; % 42±10 43±11 41±9
FHSCD; n (%) 620 (17%) 19 (10%) 886 (24%)
Unexplained syncope; n (%) 474 (13%) 31 (16%) 507 (14%)
NYHA: New York Heart Association, ICD: implantable cardioverter defibrillator, AF: Atrial fibrillation, 
NSVT: non-sustained ventricular tachycardia, LA: left atrium, LVOTgmax: maximal instantaneous left 
ventricular outflow tract gradient at rest or Valsalva, LVedd: left ventricular end diastolic dimension, 
MWT: maximal wall thickness, FS: fractional shortening, FHSCD: family history of sudden cardiac 
death, SCD: sudden cardiac death.*HCM Risk-SCD is currently not recommended in patients 
underrepresented in the development cohort (left atrial diameter>67mm, left ventricular outflow tract 









Table 2. The baseline clinical characteristics of patients with and without the SCD end-point at 5 
years of follow-up 
Baseline clinical characteristic Patients without SCD 
end-points n=3630 (98%) 
Patients with SCD end-
points within 5 years 
n=73 (2%) 
Male 2196 (61%) 45 (62%)
Age; years 52±15 46±15
NYHA III/IV 647 (19%) 13 (18%)
Myectomy 76 (2%) 1 (1%)
Alcohol septal ablation 21 (0.6%) 2 (3%)
Amiodarone 279 (8%) 18 (25%)
Permanent /persistent AF 415 (12%) 18 (25%)
NSVT 558 (22%) 24 (44%)
LA diameter; mm 43±8 44±7
LVOTGmax; mmHg 12 (7, 55) 11 (9, 73)
LVedd; mm 45±7 46±7
MWT; mm 20±4 22±5
FS; % 42±10 43±12
FHSCD 600 (17%) 20 (27%)
Unexplained syncope 457 (13%) 17 (23%)
NYHA: New York Heart Association, ICD: implantable cardioverter defibrillator, AF: Atrial fibrillation, 
NSVT: non-sustained ventricular tachycardia, LA: left atrium, LVOTgmax: maximal instantaneous left 
ventricular outflow tract gradient at rest or Valsalva, LVedd: left ventricular end diastolic dimension, 
MWT: maximal wall thickness, FS: fractional shortening, FHSCD: family history of sudden cardiac 
death, SCD: sudden cardiac death. 





Table 3. The baseline clinical characteristics of patients with and without septal reduction
Baseline clinical characteristic Patients without 
septal reduction 
therapy (n=3033) 
Patients with septal 
reduction therapy 
prior to first 
evaluation (n=98)




Time interval between septal 
reduction and baseline 
evaluation (years)
NA 2.2 (0.4, 8.0) 0.11 (0.01, 1.3)
Male 1883 (62%) 44 (45%) 314 (55%)
Age; years 52±15 52±15 51±14
NYHA III/IV 319 (11%) 27 (26%) 315 (55%)
Amiodarone 216 (7%) 21 (22%) 60 (10%)
Permanent /persistent AF 380 (13%) 19 (21%) 34 (6%)
NSVT 494 (22%) 21 (37%) 67 (22%)
LA diameter; mm 43±8 47±9 47±8
LVOTGmax; mmHg 8 (6, 35) 17 (8, 72) 64 (29, 100)
LVedd; mm 45±7 45±7 43±7
MWT; mm 19±4 19±5 21±4
FS; % 41±10 40±13 45±9
FHSCD 508 (17%) 18 (19%) 94 (17%)
Unexplained syncope 364 (12%) 12 (13%) 98 (18%)
NYHA: New York Heart Association, ICD: implantable cardioverter defibrillator, AF: Atrial fibrillation, 
NSVT: non-sustained ventricular tachycardia, LA: left atrium, LVOTgmax: left ventricular outflow tract 
gradient at rest or Valsalva, LVedd: left ventricular end diastolic dimension, MWT: maximal wall 
thickness, FS: fractional shortening, FHSCD: family history of sudden cardiac death.





Table 4. Events in patients with complete dataset to calculate HCM Risk-SCD
Calculated HCM Risk-SCD at 5 years in 2147 patients
Risk category <4% 4% to <6% 
2014 ESC guideline 
recommendation on 
ICD implantation 
Not recommended if there 
are no other clinical features 
that are of proven prognostic 
importance (III, B)  
May be considered in 
individual patients (IIb, B)
Should be considered 
(IIa, B)
Number of patients 1524 (71%) 326 (15%) 297 (14%)
SCD end-points within 
5 years
16 (1%) 5* (1.5%) 23 (7%)
5 year incidence of 
SCD
1.4% (95% CI: 0.8, 2.2) 1.8% (95% CI: 0.7, 4.3) 8.9% (95% CI: 5.96, 13.1)
Annual rate of SCD 
end-point within 5 
years of evaluation
0.27% (95% CI: 0.17, 0.44) 0.39% (95% CI: 0.16, 0.93) 1.92% (95% CI:  1.27, 2.88)
*4/5 patients had a predicted 5-year SCD risk >5%; in total, 428 patients had 5-\HDUULVNZLWK
SCD end-points 






Figure 1. Calibration by risk group. 
Circles represent observed and diamonds represent predicted probabilities of sudden cardiac 
death in 5 years using a random multiple imputation dataset. The four risk groups (1-4) were 
created using model-based predicted probabilities (0-2%, 2-4%, 4-6% and >6% 5-year risk of 
SCD). These groups are selected for the purposes of validation rather than clinical decision 
making. 
Figure 2. Kaplan-Meier curve showing SCD end-points within 5 years of baseline 
evaluation, stratified according to the estimated 5 year risk of SCD. 
Patients with complete data for the calculation of HCM Risk-SCD estimates (n= 2147) were 
classified in three risk groups in accordance to the 2014 ESC guidelines (HCM Risk-SCD <4%, 
WR7KHDW-risk table shows the number of SCD end-points in parentheses. 
Figure 3. The annual rate of SCD end-points within 5 years of baseline evaluation stratified 
according the estimated 5 year risk of SCD.
The annual risk of SCD end-points and the 95% confidence intervals for the three 2014 ESC 
guidelines risk groups (HCM Risk-6&'WRDUHVKRZQFRPSOHWHFDVH
analysis n=2147).
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